{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:10:38Z","timestamp":1789593038929,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["project: ZELL-THEMA"],"award-info":[{"award-number":["project: ZELL-THEMA"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR2886"],"award-info":[{"award-number":["FOR2886"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RTG2408"],"award-info":[{"award-number":["RTG2408"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR221"],"award-info":[{"award-number":["TRR221"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Leibnitz award to G.S."],"award-info":[{"award-number":["Leibnitz award to G.S."]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.103000","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:47:51Z","timestamp":1787323671000},"page":"103000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series"],"prefix":"10.1016","volume":"7","author":[{"given":"Tobias","family":"Hegelmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremias","family":"Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Duscha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Desel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sgodzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Al-Dubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Borie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9629-3298","authenticated-orcid":false,"given":"Aiden","family":"Haghikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103000_bib1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103000_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(23)00125-4","article-title":"New therapies for autoimmune myasthenia gravis","volume":"22","author":"Verschuuren","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib5","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103000_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103000_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2026.103000_bib8","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103000_bib9","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2026.103000_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41584-024-01179-5","article-title":"The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"D\u00f6rner","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.xcrm.2026.103000_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103000_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xcrm.2026.103000_bib14","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.xcrm.2026.103000_bib15","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103000_bib18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103000_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2026.103000_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.xcrm.2026.103000_bib22","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103000_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xcrm.2026.103000_bib24","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/cen3.12774","article-title":"Performance evaluation of the EUROIMMUN anti-acetylcholine receptor enzyme-linked immunoassay","volume":"15","author":"Kawaguchi","year":"2024","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.xcrm.2026.103000_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.xcrm.2026.103000_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2026.103000_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200436","article-title":"AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis","volume":"12","author":"Khani-Habibabadi","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.xcrm.2026.103000_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41577-025-01137-6","article-title":"B cells in non-lymphoid tissues","volume":"25","author":"Samiea","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.103000_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib32","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103000_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41434-025-00586-x","article-title":"Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA\u2019s conclusions from the evaluation of 38 suspected cases","volume":"33","author":"Berg","year":"2026","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103000_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103000_bib35","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1212\/WNL.0000000000202824","article-title":"Risk of Infection in Patients with Myasthenia Gravis With and Without Thymoma (P2-8.008)","volume":"100","author":"Clifford","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2026.103000_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.xcrm.2026.103000_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2026.103000_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.xcrm.2026.103000_bib39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcyt.2024.09.008","article-title":"Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders","volume":"27","author":"Mougiakakos","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2026.103000_bib40","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","article-title":"RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types","volume":"26","author":"Monaco","year":"2019","journal-title":"Cell Rep."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:47:25Z","timestamp":1789591645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004179"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103000","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103000"}}